Viewing Study NCT05194995


Ignite Creation Date: 2025-12-24 @ 2:16 PM
Ignite Modification Date: 2026-03-05 @ 6:40 PM
Study NCT ID: NCT05194995
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-04
First Post: 2021-12-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Sponsor: Allist Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module